| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| In Situ Hybridization, Fluorescence | 52 | 2022 | 2649 | 2.390 |
Why?
|
| Proto-Oncogene Proteins c-met | 16 | 2020 | 578 | 2.370 |
Why?
|
| Lung Neoplasms | 72 | 2023 | 13096 | 2.320 |
Why?
|
| Pyrazoles | 22 | 2019 | 1973 | 2.230 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 40 | 2023 | 5221 | 2.140 |
Why?
|
| Isocitrate Dehydrogenase | 23 | 2019 | 871 | 2.020 |
Why?
|
| Pyridines | 22 | 2021 | 2822 | 1.970 |
Why?
|
| Gene Rearrangement | 20 | 2019 | 1179 | 1.890 |
Why?
|
| Gene Amplification | 25 | 2020 | 1062 | 1.820 |
Why?
|
| Mutation | 126 | 2023 | 29784 | 1.810 |
Why?
|
| Protein Kinase Inhibitors | 48 | 2023 | 5529 | 1.700 |
Why?
|
| Adenocarcinoma | 34 | 2019 | 6352 | 1.680 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 29 | 2022 | 1660 | 1.660 |
Why?
|
| Protein-Tyrosine Kinases | 14 | 2019 | 2455 | 1.570 |
Why?
|
| High-Throughput Nucleotide Sequencing | 28 | 2023 | 3598 | 1.530 |
Why?
|
| Drug Resistance, Neoplasm | 34 | 2020 | 5169 | 1.340 |
Why?
|
| Bile Duct Neoplasms | 9 | 2023 | 567 | 1.210 |
Why?
|
| Cholangiocarcinoma | 9 | 2023 | 516 | 1.200 |
Why?
|
| Antibodies, Viral | 11 | 2023 | 3176 | 1.160 |
Why?
|
| Brain Neoplasms | 28 | 2021 | 8860 | 1.080 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 25 | 2023 | 1692 | 1.070 |
Why?
|
| Gene Fusion | 9 | 2021 | 371 | 0.980 |
Why?
|
| Oncogene Proteins, Fusion | 15 | 2022 | 1581 | 0.970 |
Why?
|
| Proto-Oncogene Proteins B-raf | 22 | 2023 | 2041 | 0.970 |
Why?
|
| Proto-Oncogene Proteins | 22 | 2019 | 4553 | 0.940 |
Why?
|
| Glioblastoma | 16 | 2021 | 3481 | 0.880 |
Why?
|
| Adenocarcinoma, Mucinous | 5 | 2017 | 505 | 0.870 |
Why?
|
| Glioma | 16 | 2019 | 3401 | 0.870 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 4 | 2019 | 250 | 0.810 |
Why?
|
| DNA Mutational Analysis | 29 | 2020 | 4188 | 0.800 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 18 | 2020 | 890 | 0.790 |
Why?
|
| Genes, erbB-1 | 7 | 2017 | 161 | 0.780 |
Why?
|
| Oligodendroglioma | 6 | 2019 | 279 | 0.770 |
Why?
|
| Glutarates | 7 | 2018 | 236 | 0.750 |
Why?
|
| Gene Products, nef | 9 | 2000 | 110 | 0.730 |
Why?
|
| Neoplastic Cells, Circulating | 9 | 2023 | 933 | 0.640 |
Why?
|
| Receptors, Growth Factor | 4 | 2011 | 334 | 0.620 |
Why?
|
| Genetic Testing | 6 | 2019 | 3443 | 0.620 |
Why?
|
| Neoplasms | 21 | 2023 | 21672 | 0.610 |
Why?
|
| Genomics | 6 | 2023 | 5722 | 0.600 |
Why?
|
| Humans | 286 | 2023 | 744220 | 0.600 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2014 | 713 | 0.580 |
Why?
|
| Quinazolines | 8 | 2016 | 1356 | 0.580 |
Why?
|
| Aged, 80 and over | 67 | 2021 | 57768 | 0.580 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2015 | 178 | 0.570 |
Why?
|
| Molecular Targeted Therapy | 15 | 2020 | 2727 | 0.570 |
Why?
|
| Middle Aged | 134 | 2023 | 213367 | 0.570 |
Why?
|
| Mosaicism | 3 | 2021 | 441 | 0.570 |
Why?
|
| Receptor, trkA | 4 | 2019 | 164 | 0.560 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2020 | 704 | 0.550 |
Why?
|
| Bile Ducts, Intrahepatic | 5 | 2023 | 295 | 0.540 |
Why?
|
| Chordoma | 3 | 2019 | 359 | 0.540 |
Why?
|
| Molecular Diagnostic Techniques | 7 | 2019 | 602 | 0.530 |
Why?
|
| Female | 172 | 2023 | 380197 | 0.520 |
Why?
|
| Aged | 112 | 2023 | 163253 | 0.520 |
Why?
|
| Simian immunodeficiency virus | 9 | 2000 | 846 | 0.510 |
Why?
|
| Antineoplastic Agents | 25 | 2023 | 13668 | 0.510 |
Why?
|
| Adenocarcinoma, Clear Cell | 3 | 2021 | 221 | 0.510 |
Why?
|
| Cytodiagnosis | 2 | 2016 | 435 | 0.510 |
Why?
|
| Neoplasm Recurrence, Local | 15 | 2022 | 9230 | 0.510 |
Why?
|
| Chromosomes, Human, Pair 19 | 3 | 2019 | 367 | 0.500 |
Why?
|
| Genotype | 26 | 2021 | 12956 | 0.500 |
Why?
|
| Genes, ras | 5 | 2015 | 690 | 0.490 |
Why?
|
| Lactams, Macrocyclic | 5 | 2018 | 320 | 0.490 |
Why?
|
| Gene Dosage | 7 | 2013 | 1251 | 0.490 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 3 | 2009 | 85 | 0.480 |
Why?
|
| ras Proteins | 14 | 2015 | 1060 | 0.480 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 4 | 2019 | 188 | 0.470 |
Why?
|
| DNA, Neoplasm | 11 | 2019 | 1758 | 0.470 |
Why?
|
| Gallbladder Neoplasms | 2 | 2014 | 183 | 0.470 |
Why?
|
| Translocation, Genetic | 6 | 2022 | 1420 | 0.470 |
Why?
|
| Genes, Neoplasm | 3 | 2014 | 376 | 0.470 |
Why?
|
| Adult | 102 | 2022 | 214035 | 0.470 |
Why?
|
| Male | 142 | 2022 | 350027 | 0.460 |
Why?
|
| Chromosomes, Human, Pair 1 | 3 | 2019 | 658 | 0.460 |
Why?
|
| Esophageal Neoplasms | 5 | 2020 | 1582 | 0.450 |
Why?
|
| Exons | 2 | 2016 | 2439 | 0.450 |
Why?
|
| Phosphatidylinositol 3-Kinases | 14 | 2018 | 2938 | 0.450 |
Why?
|
| Seroepidemiologic Studies | 4 | 2023 | 402 | 0.440 |
Why?
|
| Cell Line, Tumor | 36 | 2021 | 16687 | 0.430 |
Why?
|
| Immunohistochemistry | 29 | 2021 | 11368 | 0.420 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 2 | 2011 | 379 | 0.420 |
Why?
|
| Stomach Neoplasms | 4 | 2020 | 1333 | 0.420 |
Why?
|
| DNA Copy Number Variations | 8 | 2021 | 1940 | 0.420 |
Why?
|
| RNA-Binding Protein EWS | 4 | 2021 | 216 | 0.410 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2023 | 11493 | 0.410 |
Why?
|
| Point-of-Care Systems | 1 | 2020 | 1176 | 0.410 |
Why?
|
| Chromosome Deletion | 5 | 2019 | 1401 | 0.410 |
Why?
|
| Aneuploidy | 2 | 2019 | 530 | 0.410 |
Why?
|
| Chromosome Aberrations | 3 | 2018 | 1814 | 0.410 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2023 | 4033 | 0.410 |
Why?
|
| Comparative Genomic Hybridization | 5 | 2019 | 496 | 0.400 |
Why?
|
| Wilms Tumor | 3 | 2013 | 373 | 0.400 |
Why?
|
| Salivary Gland Neoplasms | 3 | 2022 | 298 | 0.400 |
Why?
|
| Breast Neoplasms | 15 | 2023 | 20817 | 0.400 |
Why?
|
| Genome, Human | 7 | 2021 | 4420 | 0.390 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 3 | 2009 | 91 | 0.390 |
Why?
|
| DNA Methylation | 9 | 2021 | 4289 | 0.390 |
Why?
|
| Pancreatic Neoplasms | 6 | 2015 | 5257 | 0.380 |
Why?
|
| Papillomavirus Infections | 5 | 2023 | 1587 | 0.380 |
Why?
|
| Prognosis | 29 | 2023 | 29050 | 0.380 |
Why?
|
| Sequence Analysis, DNA | 11 | 2021 | 4803 | 0.380 |
Why?
|
| Receptor, EphB4 | 2 | 2015 | 38 | 0.370 |
Why?
|
| Tumor Suppressor Protein p53 | 12 | 2023 | 2948 | 0.370 |
Why?
|
| Small Cell Lung Carcinoma | 3 | 2015 | 388 | 0.370 |
Why?
|
| Receptor, erbB-2 | 10 | 2020 | 2416 | 0.370 |
Why?
|
| Genetic Variation | 7 | 2017 | 6546 | 0.370 |
Why?
|
| Odontogenic Tumors | 2 | 2021 | 45 | 0.370 |
Why?
|
| Polymerase Chain Reaction | 13 | 2021 | 6172 | 0.360 |
Why?
|
| Oncogene Fusion | 5 | 2019 | 99 | 0.360 |
Why?
|
| Liver Neoplasms | 9 | 2017 | 4252 | 0.360 |
Why?
|
| Melanoma | 4 | 2023 | 5475 | 0.350 |
Why?
|
| Antibodies, Neutralizing | 5 | 2022 | 1978 | 0.350 |
Why?
|
| Carcinoma, Papillary | 3 | 2016 | 783 | 0.340 |
Why?
|
| Receptor, trkC | 2 | 2019 | 68 | 0.340 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2014 | 1143 | 0.340 |
Why?
|
| Medical Informatics | 1 | 2016 | 743 | 0.340 |
Why?
|
| Gene Expression Regulation, Neoplastic | 16 | 2020 | 8426 | 0.340 |
Why?
|
| Chromosomes, Human, X | 2 | 2007 | 296 | 0.340 |
Why?
|
| Pharmacogenetics | 1 | 2013 | 676 | 0.330 |
Why?
|
| Uterine Neoplasms | 3 | 2018 | 1513 | 0.330 |
Why?
|
| Hydatidiform Mole | 1 | 2011 | 279 | 0.320 |
Why?
|
| Genetic Heterogeneity | 5 | 2019 | 733 | 0.320 |
Why?
|
| Disease Progression | 16 | 2023 | 13280 | 0.320 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 4 | 2018 | 379 | 0.310 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 2 | 2022 | 102 | 0.310 |
Why?
|
| Neoplasm Staging | 15 | 2019 | 11007 | 0.300 |
Why?
|
| Chimera | 1 | 2009 | 485 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-ret | 2 | 2019 | 220 | 0.300 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2020 | 989 | 0.290 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2007 | 245 | 0.290 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2023 | 477 | 0.290 |
Why?
|
| Gene Deletion | 3 | 2019 | 2751 | 0.290 |
Why?
|
| Acrylamides | 3 | 2018 | 255 | 0.290 |
Why?
|
| Microsatellite Instability | 6 | 2014 | 684 | 0.290 |
Why?
|
| Bile Ducts | 2 | 2020 | 284 | 0.290 |
Why?
|
| Skin Neoplasms | 3 | 2023 | 5670 | 0.290 |
Why?
|
| Tumor Suppressor Proteins | 6 | 2018 | 2848 | 0.280 |
Why?
|
| Xenograft Model Antitumor Assays | 14 | 2020 | 3557 | 0.280 |
Why?
|
| Eosinophilia | 2 | 2022 | 542 | 0.280 |
Why?
|
| Dacarbazine | 4 | 2017 | 567 | 0.270 |
Why?
|
| Immunoglobulin M | 5 | 2020 | 1538 | 0.260 |
Why?
|
| MAP Kinase Kinase 1 | 6 | 2017 | 337 | 0.260 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 4 | 2019 | 105 | 0.260 |
Why?
|
| Neoplasm Metastasis | 8 | 2020 | 4841 | 0.250 |
Why?
|
| Young Adult | 33 | 2023 | 56436 | 0.250 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2014 | 6535 | 0.240 |
Why?
|
| Pyrimidines | 9 | 2020 | 2940 | 0.240 |
Why?
|
| Carcinoma | 4 | 2023 | 2375 | 0.240 |
Why?
|
| Rhabdomyosarcoma | 2 | 2022 | 382 | 0.240 |
Why?
|
| Promoter Regions, Genetic | 7 | 2019 | 5867 | 0.240 |
Why?
|
| Head and Neck Neoplasms | 3 | 2023 | 2732 | 0.240 |
Why?
|
| Smad4 Protein | 4 | 2020 | 163 | 0.230 |
Why?
|
| Polymorphism, Genetic | 3 | 2011 | 4328 | 0.230 |
Why?
|
| Thyroid Neoplasms | 4 | 2019 | 2281 | 0.230 |
Why?
|
| Pathology, Clinical | 2 | 2018 | 368 | 0.230 |
Why?
|
| Disease-Free Survival | 9 | 2018 | 6893 | 0.220 |
Why?
|
| Carcinoma in Situ | 3 | 2023 | 805 | 0.220 |
Why?
|
| Molecular Probes | 2 | 2019 | 316 | 0.220 |
Why?
|
| Colonic Neoplasms | 5 | 2018 | 2538 | 0.220 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2020 | 3871 | 0.220 |
Why?
|
| Vaccines, Synthetic | 2 | 2022 | 634 | 0.210 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2022 | 3523 | 0.210 |
Why?
|
| Smoking | 7 | 2019 | 8986 | 0.210 |
Why?
|
| Software | 1 | 2016 | 4442 | 0.210 |
Why?
|
| Pancreatic Cyst | 2 | 2016 | 368 | 0.210 |
Why?
|
| Meningioma | 2 | 2022 | 1209 | 0.200 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 3 | 2017 | 86 | 0.200 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2022 | 88 | 0.200 |
Why?
|
| Pharmacy | 1 | 2023 | 91 | 0.200 |
Why?
|
| GTP Phosphohydrolases | 5 | 2016 | 508 | 0.200 |
Why?
|
| Meningeal Neoplasms | 2 | 2022 | 1241 | 0.200 |
Why?
|
| Bone Cysts | 1 | 2021 | 47 | 0.190 |
Why?
|
| Benzimidazoles | 3 | 2019 | 851 | 0.190 |
Why?
|
| Colorectal Neoplasms | 6 | 2018 | 6773 | 0.190 |
Why?
|
| Retinoblastoma Binding Proteins | 2 | 2019 | 97 | 0.190 |
Why?
|
| Signal Transduction | 19 | 2020 | 23404 | 0.190 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 2021 | 83 | 0.190 |
Why?
|
| Sensitivity and Specificity | 9 | 2021 | 14726 | 0.190 |
Why?
|
| Retrospective Studies | 30 | 2023 | 77426 | 0.190 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2023 | 234 | 0.190 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 738 | 0.190 |
Why?
|
| Chromosomes, Artificial, Bacterial | 2 | 2019 | 126 | 0.190 |
Why?
|
| Nanopores | 1 | 2021 | 50 | 0.190 |
Why?
|
| Thoracic Neoplasms | 1 | 2023 | 268 | 0.190 |
Why?
|
| Craniopharyngioma | 1 | 2023 | 281 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2016 | 987 | 0.180 |
Why?
|
| Survival Rate | 13 | 2020 | 12781 | 0.180 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2017 | 627 | 0.180 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2023 | 286 | 0.180 |
Why?
|
| Immunologic Tests | 1 | 2020 | 103 | 0.180 |
Why?
|
| Estrogen Receptor alpha | 3 | 2019 | 577 | 0.180 |
Why?
|
| Remote Sensing Technology | 1 | 2021 | 90 | 0.180 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2019 | 2108 | 0.180 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2021 | 159 | 0.180 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2015 | 740 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2021 | 1434 | 0.180 |
Why?
|
| Septins | 1 | 2019 | 54 | 0.180 |
Why?
|
| Carcinoma, Pancreatic Ductal | 4 | 2015 | 1634 | 0.170 |
Why?
|
| Blood Specimen Collection | 1 | 2021 | 246 | 0.170 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 5319 | 0.170 |
Why?
|
| Chromogranins | 2 | 2017 | 163 | 0.170 |
Why?
|
| Telomerase | 3 | 2018 | 729 | 0.170 |
Why?
|
| RNA Helicases | 1 | 2020 | 142 | 0.170 |
Why?
|
| Astrocytoma | 4 | 2013 | 789 | 0.170 |
Why?
|
| MAP Kinase Signaling System | 2 | 2018 | 1525 | 0.170 |
Why?
|
| Humerus | 1 | 2021 | 266 | 0.170 |
Why?
|
| Laboratory Proficiency Testing | 1 | 2018 | 19 | 0.170 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2020 | 188 | 0.170 |
Why?
|
| NFATC Transcription Factors | 1 | 2021 | 381 | 0.170 |
Why?
|
| Down-Regulation | 7 | 2000 | 3001 | 0.170 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 221 | 0.170 |
Why?
|
| Jaw Neoplasms | 1 | 2019 | 70 | 0.170 |
Why?
|
| DNA-Binding Proteins | 9 | 2022 | 9647 | 0.170 |
Why?
|
| Mesothelioma | 1 | 2015 | 818 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2019 | 2503 | 0.170 |
Why?
|
| Genital Neoplasms, Female | 2 | 2017 | 522 | 0.170 |
Why?
|
| Receptor, trkB | 1 | 2019 | 125 | 0.160 |
Why?
|
| Thrombocytosis | 1 | 2018 | 81 | 0.160 |
Why?
|
| Genes, erbB-2 | 3 | 2017 | 162 | 0.160 |
Why?
|
| Immunoglobulin G | 5 | 2020 | 4559 | 0.160 |
Why?
|
| Base Sequence | 8 | 2015 | 12801 | 0.160 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 322 | 0.160 |
Why?
|
| Fibula | 1 | 2021 | 269 | 0.160 |
Why?
|
| Reproducibility of Results | 8 | 2019 | 19907 | 0.160 |
Why?
|
| Cyst Fluid | 2 | 2016 | 76 | 0.160 |
Why?
|
| Virion | 1 | 2000 | 433 | 0.160 |
Why?
|
| Antibody Specificity | 1 | 2020 | 1095 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2019 | 318 | 0.160 |
Why?
|
| Mandibular Neoplasms | 1 | 2019 | 129 | 0.160 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 2 | 2017 | 202 | 0.160 |
Why?
|
| Cyanides | 1 | 2018 | 83 | 0.160 |
Why?
|
| Neuregulin-1 | 2 | 2017 | 142 | 0.160 |
Why?
|
| NAD | 3 | 2017 | 594 | 0.160 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2018 | 109 | 0.160 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2014 | 2915 | 0.160 |
Why?
|
| Parotid Neoplasms | 1 | 2019 | 155 | 0.160 |
Why?
|
| Fingers | 1 | 2021 | 514 | 0.150 |
Why?
|
| Treatment Outcome | 18 | 2020 | 63119 | 0.150 |
Why?
|
| Color | 1 | 2019 | 307 | 0.150 |
Why?
|
| Guanidines | 1 | 2018 | 191 | 0.150 |
Why?
|
| Enzyme Inhibitors | 3 | 2018 | 3800 | 0.150 |
Why?
|
| Transcription Factors | 9 | 2022 | 12207 | 0.150 |
Why?
|
| Gene Expression Profiling | 9 | 2017 | 9438 | 0.150 |
Why?
|
| Adenofibroma | 1 | 2017 | 25 | 0.150 |
Why?
|
| Drug Screening Assays, Antitumor | 4 | 2014 | 731 | 0.150 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2020 | 414 | 0.150 |
Why?
|
| Phenylurea Compounds | 2 | 2019 | 527 | 0.150 |
Why?
|
| Cytogenetic Analysis | 4 | 2018 | 295 | 0.150 |
Why?
|
| Carbazoles | 2 | 2019 | 226 | 0.150 |
Why?
|
| Transcription Factors, TFII | 1 | 1997 | 60 | 0.150 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2021 | 880 | 0.150 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2017 | 45 | 0.150 |
Why?
|
| Dystrophin | 1 | 2018 | 285 | 0.150 |
Why?
|
| Immunoassay | 1 | 2020 | 752 | 0.140 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2017 | 895 | 0.140 |
Why?
|
| Barrett Esophagus | 2 | 2011 | 494 | 0.140 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 627 | 0.140 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2019 | 252 | 0.140 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2016 | 59 | 0.140 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2018 | 3760 | 0.140 |
Why?
|
| Immunity, Humoral | 1 | 2021 | 598 | 0.140 |
Why?
|
| Codon | 3 | 2014 | 611 | 0.140 |
Why?
|
| Bone Neoplasms | 2 | 2021 | 2525 | 0.140 |
Why?
|
| Piperidines | 4 | 2020 | 1605 | 0.140 |
Why?
|
| Viral Vaccines | 1 | 2022 | 636 | 0.140 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2020 | 783 | 0.140 |
Why?
|
| Aniline Compounds | 2 | 2018 | 986 | 0.140 |
Why?
|
| Neoplastic Stem Cells | 4 | 2017 | 1376 | 0.140 |
Why?
|
| Karyotyping | 2 | 2009 | 1243 | 0.140 |
Why?
|
| Fibrosarcoma | 1 | 2018 | 348 | 0.140 |
Why?
|
| Specimen Handling | 1 | 2021 | 694 | 0.140 |
Why?
|
| src Homology Domains | 4 | 2007 | 364 | 0.140 |
Why?
|
| Vesicle-Associated Membrane Protein 2 | 1 | 2015 | 19 | 0.140 |
Why?
|
| HIV-1 | 7 | 2000 | 6938 | 0.130 |
Why?
|
| Leiomyoma | 1 | 2021 | 730 | 0.130 |
Why?
|
| Cell Proliferation | 9 | 2020 | 10480 | 0.130 |
Why?
|
| Cohort Studies | 17 | 2021 | 40559 | 0.130 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2019 | 332 | 0.130 |
Why?
|
| Phosphoproteins | 3 | 2018 | 2440 | 0.130 |
Why?
|
| Mice, SCID | 5 | 2019 | 2716 | 0.130 |
Why?
|
| Point Mutation | 4 | 2016 | 1624 | 0.130 |
Why?
|
| Lectins, C-Type | 2 | 2015 | 588 | 0.130 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 7 | 2000 | 153 | 0.130 |
Why?
|
| Tropomyosin | 1 | 2015 | 102 | 0.130 |
Why?
|
| BRCA2 Protein | 1 | 2020 | 794 | 0.130 |
Why?
|
| beta Catenin | 4 | 2014 | 1059 | 0.130 |
Why?
|
| High-Throughput Screening Assays | 1 | 2021 | 945 | 0.130 |
Why?
|
| Genes, nef | 3 | 2000 | 55 | 0.130 |
Why?
|
| Massachusetts | 4 | 2020 | 8663 | 0.130 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2015 | 1352 | 0.130 |
Why?
|
| RNA, Small Interfering | 7 | 2020 | 3505 | 0.130 |
Why?
|
| Biliary Tract | 1 | 2015 | 134 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2018 | 1039 | 0.130 |
Why?
|
| Administration, Oral | 2 | 2014 | 3913 | 0.130 |
Why?
|
| Workflow | 2 | 2017 | 847 | 0.130 |
Why?
|
| Sequence Analysis, RNA | 3 | 2019 | 2013 | 0.130 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2015 | 318 | 0.130 |
Why?
|
| Prospective Studies | 17 | 2022 | 53280 | 0.130 |
Why?
|
| Esophagogastric Junction | 2 | 2020 | 313 | 0.120 |
Why?
|
| False Negative Reactions | 1 | 2015 | 587 | 0.120 |
Why?
|
| Pituitary Neoplasms | 1 | 2023 | 1346 | 0.120 |
Why?
|
| Femur | 1 | 2021 | 1297 | 0.120 |
Why?
|
| Phenotype | 14 | 2019 | 16365 | 0.120 |
Why?
|
| DNA Helicases | 1 | 2020 | 861 | 0.120 |
Why?
|
| Cecal Neoplasms | 1 | 2014 | 29 | 0.120 |
Why?
|
| Mice | 22 | 2020 | 81178 | 0.120 |
Why?
|
| Liver Circulation | 1 | 2014 | 163 | 0.120 |
Why?
|
| Benzoquinones | 2 | 2014 | 201 | 0.120 |
Why?
|
| Indazoles | 1 | 2015 | 287 | 0.120 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2014 | 60 | 0.120 |
Why?
|
| Neoplasm Proteins | 3 | 2018 | 3703 | 0.120 |
Why?
|
| Gene Expression | 8 | 2018 | 7799 | 0.120 |
Why?
|
| Leiomyosarcoma | 1 | 2018 | 477 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 6 | 2020 | 6313 | 0.120 |
Why?
|
| Kidney Neoplasms | 2 | 2007 | 4245 | 0.120 |
Why?
|
| Pathology, Molecular | 2 | 2014 | 326 | 0.120 |
Why?
|
| Adenocarcinoma, Papillary | 2 | 2012 | 84 | 0.120 |
Why?
|
| Medical Oncology | 3 | 2023 | 2265 | 0.120 |
Why?
|
| Adolescent | 19 | 2023 | 85759 | 0.120 |
Why?
|
| Papillomaviridae | 4 | 2023 | 1119 | 0.110 |
Why?
|
| BRCA1 Protein | 1 | 2020 | 1149 | 0.110 |
Why?
|
| Nuclear Proteins | 5 | 2022 | 5853 | 0.110 |
Why?
|
| Molecular Sequence Data | 12 | 2015 | 18116 | 0.110 |
Why?
|
| Aminopyridines | 4 | 2018 | 542 | 0.110 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 1 | 2013 | 42 | 0.110 |
Why?
|
| Hemangiosarcoma | 1 | 2015 | 239 | 0.110 |
Why?
|
| Hepatoblastoma | 1 | 2013 | 87 | 0.110 |
Why?
|
| DNA, Mitochondrial | 1 | 2018 | 817 | 0.110 |
Why?
|
| Single-Cell Analysis | 3 | 2022 | 2183 | 0.110 |
Why?
|
| Animals | 34 | 2023 | 168788 | 0.110 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2015 | 199 | 0.110 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2015 | 504 | 0.110 |
Why?
|
| Biopsy | 7 | 2020 | 6757 | 0.110 |
Why?
|
| Apocrine Glands | 1 | 2012 | 31 | 0.110 |
Why?
|
| Histocompatibility Antigens Class I | 7 | 2000 | 1366 | 0.110 |
Why?
|
| Adenosine Triphosphate | 1 | 2019 | 2025 | 0.110 |
Why?
|
| Lung | 3 | 2018 | 9852 | 0.110 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2013 | 118 | 0.110 |
Why?
|
| Mice, Nude | 5 | 2020 | 3689 | 0.110 |
Why?
|
| Eccrine Glands | 1 | 2012 | 45 | 0.110 |
Why?
|
| Myeloproliferative Disorders | 1 | 2018 | 605 | 0.110 |
Why?
|
| Oncogenes | 3 | 2014 | 1265 | 0.110 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3132 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2020 | 4752 | 0.110 |
Why?
|
| Carcinoma, Ductal | 1 | 2012 | 101 | 0.110 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3239 | 0.100 |
Why?
|
| Follow-Up Studies | 12 | 2020 | 39045 | 0.100 |
Why?
|
| DNA Repair Enzymes | 4 | 2018 | 349 | 0.100 |
Why?
|
| Lactams | 3 | 2018 | 156 | 0.100 |
Why?
|
| Blotting, Western | 6 | 2017 | 5180 | 0.100 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2019 | 1860 | 0.100 |
Why?
|
| Bone Marrow Transplantation | 2 | 2011 | 2763 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 3 | 2015 | 3614 | 0.100 |
Why?
|
| Oncolytic Virotherapy | 1 | 2017 | 497 | 0.100 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2014 | 434 | 0.100 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2013 | 644 | 0.100 |
Why?
|
| Capillary Leak Syndrome | 1 | 2011 | 31 | 0.100 |
Why?
|
| Graft Survival | 2 | 2015 | 3740 | 0.100 |
Why?
|
| Pulmonary Circulation | 1 | 2014 | 739 | 0.100 |
Why?
|
| Nucleic Acid Hybridization | 3 | 2007 | 1375 | 0.100 |
Why?
|
| Caveolin 1 | 1 | 2013 | 264 | 0.100 |
Why?
|
| Databases, Genetic | 2 | 2019 | 1782 | 0.100 |
Why?
|
| Retinoblastoma Protein | 1 | 2015 | 704 | 0.100 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 1378 | 0.100 |
Why?
|
| DNA, Satellite | 1 | 2011 | 69 | 0.100 |
Why?
|
| Survival Analysis | 7 | 2020 | 10250 | 0.100 |
Why?
|
| Fluorescent Dyes | 1 | 2019 | 1917 | 0.100 |
Why?
|
| Membrane Proteins | 8 | 2016 | 7879 | 0.100 |
Why?
|
| Diagnosis, Differential | 6 | 2018 | 12961 | 0.100 |
Why?
|
| Deoxycytidine | 2 | 2014 | 825 | 0.100 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2015 | 1475 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 6 | 2015 | 9275 | 0.090 |
Why?
|
| Regression Analysis | 1 | 2020 | 6461 | 0.090 |
Why?
|
| Drug Resistance | 2 | 2014 | 1608 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2020 | 12244 | 0.090 |
Why?
|
| Reimbursement Mechanisms | 1 | 2016 | 670 | 0.090 |
Why?
|
| Amino Acid Sequence | 9 | 2015 | 13817 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 3 | 2023 | 647 | 0.090 |
Why?
|
| Radiography | 3 | 2011 | 7022 | 0.090 |
Why?
|
| DNA Mismatch Repair | 2 | 2014 | 426 | 0.090 |
Why?
|
| Carcinosarcoma | 1 | 2010 | 108 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2011 | 322 | 0.090 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2014 | 594 | 0.090 |
Why?
|
| DNA Probes | 1 | 2011 | 560 | 0.090 |
Why?
|
| Benzamides | 1 | 2015 | 1378 | 0.090 |
Why?
|
| Gliosis | 1 | 2011 | 245 | 0.090 |
Why?
|
| Pulmonary Fibrosis | 1 | 2014 | 529 | 0.090 |
Why?
|
| Virus Replication | 5 | 2000 | 2534 | 0.090 |
Why?
|
| Tumor Burden | 4 | 2017 | 1914 | 0.090 |
Why?
|
| Stress, Physiological | 1 | 2017 | 1404 | 0.090 |
Why?
|
| Sequence Deletion | 3 | 2013 | 1526 | 0.090 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 2008 | 0.090 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2011 | 108 | 0.090 |
Why?
|
| Leukemia, Myeloid | 1 | 2012 | 705 | 0.090 |
Why?
|
| Radiology | 1 | 2023 | 2099 | 0.080 |
Why?
|
| Piperazines | 4 | 2021 | 2491 | 0.080 |
Why?
|
| DNA Modification Methylases | 3 | 2018 | 206 | 0.080 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2014 | 736 | 0.080 |
Why?
|
| Germinal Center | 1 | 2011 | 377 | 0.080 |
Why?
|
| Sulfones | 3 | 2016 | 437 | 0.080 |
Why?
|
| Cerebellar Neoplasms | 1 | 2014 | 587 | 0.080 |
Why?
|
| Cell Adhesion Molecules | 1 | 2015 | 1602 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2023 | 535 | 0.080 |
Why?
|
| Pancreas | 1 | 2015 | 1686 | 0.080 |
Why?
|
| Cross Reactions | 2 | 2020 | 841 | 0.080 |
Why?
|
| Endometrial Neoplasms | 1 | 2018 | 1353 | 0.080 |
Why?
|
| Medulloblastoma | 1 | 2014 | 683 | 0.080 |
Why?
|
| Algorithms | 2 | 2019 | 13885 | 0.080 |
Why?
|
| Eligibility Determination | 1 | 2012 | 403 | 0.080 |
Why?
|
| Molecular Biology | 1 | 2012 | 596 | 0.080 |
Why?
|
| Lymphoma, Follicular | 1 | 2012 | 435 | 0.080 |
Why?
|
| Membrane Glycoproteins | 1 | 2019 | 3769 | 0.080 |
Why?
|
| Referral and Consultation | 2 | 2023 | 3528 | 0.080 |
Why?
|
| Tumor Microenvironment | 2 | 2018 | 3584 | 0.080 |
Why?
|
| Adenomatous Polyps | 1 | 2009 | 107 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2019 | 3023 | 0.080 |
Why?
|
| Receptors, Estrogen | 3 | 2023 | 2186 | 0.080 |
Why?
|
| Aspirin | 1 | 2020 | 3282 | 0.080 |
Why?
|
| Kidney Transplantation | 2 | 2015 | 4251 | 0.080 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2009 | 105 | 0.080 |
Why?
|
| Carboplatin | 1 | 2011 | 800 | 0.080 |
Why?
|
| RNA, Neoplasm | 1 | 2011 | 769 | 0.080 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2012 | 300 | 0.080 |
Why?
|
| Drug Monitoring | 2 | 2018 | 956 | 0.080 |
Why?
|
| Radiosurgery | 1 | 2017 | 1328 | 0.080 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1997 | 2540 | 0.080 |
Why?
|
| Drug Interactions | 1 | 2012 | 1458 | 0.080 |
Why?
|
| Genes, p16 | 2 | 2020 | 157 | 0.080 |
Why?
|
| Phosphorylation | 7 | 2015 | 8437 | 0.080 |
Why?
|
| Pneumonectomy | 1 | 2014 | 1094 | 0.080 |
Why?
|
| Research | 1 | 2016 | 1999 | 0.080 |
Why?
|
| Gene Frequency | 4 | 2015 | 3588 | 0.080 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 1670 | 0.080 |
Why?
|
| T-Lymphocytes | 4 | 2021 | 10182 | 0.080 |
Why?
|
| Advisory Committees | 1 | 2011 | 774 | 0.070 |
Why?
|
| Founder Effect | 1 | 2007 | 190 | 0.070 |
Why?
|
| Vision Disorders | 1 | 2014 | 1059 | 0.070 |
Why?
|
| RNA, Untranslated | 1 | 2011 | 454 | 0.070 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2007 | 154 | 0.070 |
Why?
|
| Calmodulin-Binding Proteins | 2 | 2019 | 249 | 0.070 |
Why?
|
| Genes, Wilms Tumor | 1 | 2007 | 94 | 0.070 |
Why?
|
| Immunoglobulin A | 2 | 2020 | 992 | 0.070 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 2007 | 1423 | 0.070 |
Why?
|
| Bone Marrow | 2 | 2014 | 2944 | 0.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2020 | 628 | 0.070 |
Why?
|
| DNA Primers | 3 | 2021 | 2892 | 0.070 |
Why?
|
| Fractures, Compression | 1 | 2008 | 133 | 0.070 |
Why?
|
| Neoplasms, Second Primary | 1 | 2014 | 1061 | 0.070 |
Why?
|
| Sarcoma | 1 | 2018 | 1897 | 0.070 |
Why?
|
| Mesoderm | 1 | 2009 | 686 | 0.070 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2006 | 25 | 0.070 |
Why?
|
| Autopsy | 3 | 2019 | 1021 | 0.070 |
Why?
|
| Brain | 4 | 2021 | 26413 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2019 | 15525 | 0.070 |
Why?
|
| Spheroids, Cellular | 2 | 2020 | 351 | 0.070 |
Why?
|
| Pandemics | 3 | 2021 | 8387 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2019 | 20123 | 0.070 |
Why?
|
| Child | 11 | 2022 | 77679 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2018 | 13036 | 0.070 |
Why?
|
| Telemedicine | 1 | 2023 | 2872 | 0.070 |
Why?
|
| Thrombosis | 1 | 2020 | 2968 | 0.070 |
Why?
|
| Zinc Fingers | 1 | 2008 | 585 | 0.070 |
Why?
|
| Colonoscopy | 1 | 2014 | 1367 | 0.070 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2014 | 808 | 0.070 |
Why?
|
| Vulvar Neoplasms | 1 | 2008 | 272 | 0.070 |
Why?
|
| MutS Homolog 2 Protein | 2 | 2018 | 200 | 0.070 |
Why?
|
| DNA, Viral | 2 | 2023 | 2226 | 0.070 |
Why?
|
| HEK293 Cells | 3 | 2021 | 4201 | 0.070 |
Why?
|
| Deglutition Disorders | 1 | 2011 | 605 | 0.070 |
Why?
|
| Receptors, Cell Surface | 1 | 2015 | 2867 | 0.070 |
Why?
|
| Endonucleases | 1 | 2008 | 381 | 0.070 |
Why?
|
| Adaptor Protein Complex alpha Subunits | 3 | 2000 | 23 | 0.070 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 2 | 2000 | 570 | 0.070 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 1086 | 0.060 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 4 | 2000 | 315 | 0.060 |
Why?
|
| Serine Endopeptidases | 1 | 2010 | 1073 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 2 | 2015 | 3846 | 0.060 |
Why?
|
| Cytokines | 2 | 2020 | 7326 | 0.060 |
Why?
|
| Lymphoma, B-Cell | 1 | 2011 | 931 | 0.060 |
Why?
|
| Tyrosine | 5 | 2000 | 1461 | 0.060 |
Why?
|
| Superoxide Dismutase | 1 | 2007 | 596 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 5396 | 0.060 |
Why?
|
| Genes, Duplicate | 1 | 2004 | 33 | 0.060 |
Why?
|
| Hyperplasia | 2 | 2023 | 1184 | 0.060 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2016 | 347 | 0.060 |
Why?
|
| Rectal Neoplasms | 1 | 2014 | 1203 | 0.060 |
Why?
|
| Computational Biology | 3 | 2019 | 3523 | 0.060 |
Why?
|
| Back Pain | 1 | 2008 | 545 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2018 | 17449 | 0.060 |
Why?
|
| Epigenesis, Genetic | 2 | 2019 | 3646 | 0.060 |
Why?
|
| Jurkat Cells | 4 | 1999 | 743 | 0.060 |
Why?
|
| Dendritic Cells | 1 | 2015 | 2725 | 0.060 |
Why?
|
| Glucose | 1 | 2016 | 4396 | 0.060 |
Why?
|
| COS Cells | 4 | 2000 | 1161 | 0.060 |
Why?
|
| Viral Load | 3 | 2022 | 3300 | 0.060 |
Why?
|
| Enzyme Activation | 3 | 2015 | 3701 | 0.060 |
Why?
|
| Cell Survival | 4 | 2016 | 5881 | 0.060 |
Why?
|
| Cell Cycle Proteins | 2 | 2016 | 3461 | 0.060 |
Why?
|
| Fatal Outcome | 3 | 2015 | 1849 | 0.060 |
Why?
|
| Cell Lineage | 2 | 2017 | 2504 | 0.060 |
Why?
|
| Thoracic Vertebrae | 1 | 2008 | 608 | 0.060 |
Why?
|
| Sirolimus | 1 | 2011 | 1563 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 2038 | 0.060 |
Why?
|
| Macaca mulatta | 5 | 2000 | 2378 | 0.060 |
Why?
|
| RNA Editing | 2 | 2014 | 148 | 0.060 |
Why?
|
| Quinazolinones | 2 | 2019 | 221 | 0.060 |
Why?
|
| Cytoskeletal Proteins | 2 | 2019 | 1364 | 0.060 |
Why?
|
| Adenoma | 1 | 2014 | 2174 | 0.060 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2008 | 744 | 0.060 |
Why?
|
| Crohn Disease | 1 | 2016 | 2303 | 0.060 |
Why?
|
| Amino Acid Substitution | 2 | 2014 | 1792 | 0.060 |
Why?
|
| Oligodendroglia | 1 | 2006 | 519 | 0.060 |
Why?
|
| Estrogen Antagonists | 1 | 2023 | 151 | 0.050 |
Why?
|
| Sequence Alignment | 2 | 2015 | 2256 | 0.050 |
Why?
|
| Molecular Sequence Annotation | 1 | 2015 | 528 | 0.050 |
Why?
|
| K562 Cells | 2 | 2018 | 634 | 0.050 |
Why?
|
| Pyrroles | 1 | 2009 | 1143 | 0.050 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2007 | 587 | 0.050 |
Why?
|
| Genetic Engineering | 1 | 2008 | 952 | 0.050 |
Why?
|
| Time Factors | 8 | 2018 | 40063 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2015 | 323 | 0.050 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2022 | 182 | 0.050 |
Why?
|
| Genetic Linkage | 1 | 2007 | 2422 | 0.050 |
Why?
|
| Positron-Emission Tomography | 3 | 2015 | 6274 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2014 | 459 | 0.050 |
Why?
|
| Predictive Value of Tests | 6 | 2018 | 15070 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2007 | 3921 | 0.050 |
Why?
|
| Oxygen | 1 | 2013 | 4187 | 0.050 |
Why?
|
| Islets of Langerhans | 1 | 2008 | 1350 | 0.050 |
Why?
|
| Disease Models, Animal | 4 | 2023 | 18027 | 0.050 |
Why?
|
| Spinal Fractures | 1 | 2008 | 696 | 0.050 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2021 | 170 | 0.050 |
Why?
|
| Cell Nucleus | 3 | 2020 | 2969 | 0.050 |
Why?
|
| Cell Movement | 3 | 2015 | 5216 | 0.050 |
Why?
|
| Kidney | 2 | 2015 | 7183 | 0.050 |
Why?
|
| Biology | 1 | 2023 | 294 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2012 | 3469 | 0.050 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2023 | 377 | 0.050 |
Why?
|
| Structure-Activity Relationship | 2 | 2019 | 3133 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2021 | 193 | 0.050 |
Why?
|
| Indoles | 1 | 2009 | 1838 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2016 | 7730 | 0.050 |
Why?
|
| Models, Molecular | 2 | 2015 | 5458 | 0.050 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 4929 | 0.050 |
Why?
|
| Proportional Hazards Models | 5 | 2014 | 12355 | 0.050 |
Why?
|
| Salivary Glands | 1 | 2021 | 229 | 0.050 |
Why?
|
| Electroporation | 1 | 2021 | 251 | 0.050 |
Why?
|
| Gene Silencing | 1 | 2007 | 1538 | 0.050 |
Why?
|
| Neuroblastoma | 1 | 2008 | 1226 | 0.050 |
Why?
|
| Child, Preschool | 6 | 2021 | 40992 | 0.050 |
Why?
|
| Protein Conformation | 3 | 2014 | 4012 | 0.040 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2020 | 103 | 0.040 |
Why?
|
| Sex Factors | 2 | 2015 | 10396 | 0.040 |
Why?
|
| Metabolomics | 2 | 2020 | 1483 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 340 | 0.040 |
Why?
|
| Immunophenotyping | 2 | 2016 | 1880 | 0.040 |
Why?
|
| Chromatography, Affinity | 1 | 2020 | 549 | 0.040 |
Why?
|
| HIV Long-Term Survivors | 1 | 2000 | 126 | 0.040 |
Why?
|
| Mutation, Missense | 3 | 2018 | 2563 | 0.040 |
Why?
|
| Mammary Glands, Animal | 1 | 2020 | 277 | 0.040 |
Why?
|
| Astrocytes | 1 | 2006 | 1270 | 0.040 |
Why?
|
| Lymphoma | 1 | 2008 | 1873 | 0.040 |
Why?
|
| Sex Chromatin | 1 | 2018 | 20 | 0.040 |
Why?
|
| Pyridones | 2 | 2017 | 712 | 0.040 |
Why?
|
| Graft Rejection | 2 | 2011 | 4399 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 4477 | 0.040 |
Why?
|
| Pyridazines | 1 | 2020 | 202 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2011 | 2214 | 0.040 |
Why?
|
| Genes, myc | 1 | 2020 | 399 | 0.040 |
Why?
|
| Cell Differentiation | 3 | 2016 | 11478 | 0.040 |
Why?
|
| Stereotaxic Techniques | 1 | 2020 | 535 | 0.040 |
Why?
|
| Ethylnitrosourea | 1 | 2018 | 51 | 0.040 |
Why?
|
| Acute Kidney Injury | 1 | 2011 | 1971 | 0.040 |
Why?
|
| Chromosomal Instability | 1 | 2019 | 184 | 0.040 |
Why?
|
| Haploidy | 1 | 2018 | 136 | 0.040 |
Why?
|
| Biotechnology | 1 | 2020 | 280 | 0.040 |
Why?
|
| Calcitonin | 1 | 2019 | 336 | 0.040 |
Why?
|
| Mitotic Index | 1 | 2018 | 172 | 0.040 |
Why?
|
| Coronavirus | 1 | 2020 | 158 | 0.040 |
Why?
|
| Cell Hypoxia | 1 | 2020 | 675 | 0.040 |
Why?
|
| Immunoblotting | 2 | 2012 | 1682 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2021 | 1107 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2020 | 755 | 0.040 |
Why?
|
| Phthalazines | 1 | 2020 | 363 | 0.040 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2011 | 625 | 0.040 |
Why?
|
| Remission Induction | 1 | 2023 | 2389 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2022 | 1035 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2017 | 2619 | 0.040 |
Why?
|
| Chromosomes, Human | 1 | 2019 | 457 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2009 | 3690 | 0.040 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2017 | 205 | 0.040 |
Why?
|
| Transcription Factor TFIIH | 1 | 1997 | 30 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2012 | 774 | 0.040 |
Why?
|
| Capillaries | 1 | 2020 | 774 | 0.040 |
Why?
|
| Risk Factors | 7 | 2023 | 72280 | 0.040 |
Why?
|
| Transcription Factor TFIIIA | 1 | 2016 | 25 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2017 | 203 | 0.040 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2009 | 443 | 0.040 |
Why?
|
| Receptors, Steroid | 1 | 2017 | 155 | 0.040 |
Why?
|
| E2F Transcription Factors | 1 | 2017 | 277 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2017 | 170 | 0.040 |
Why?
|
| Clinical Trials as Topic | 4 | 2017 | 7908 | 0.040 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 1999 | 442 | 0.040 |
Why?
|
| Binding Sites | 4 | 2015 | 6116 | 0.040 |
Why?
|
| Virulence | 1 | 2000 | 1333 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 892 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2022 | 847 | 0.040 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2018 | 713 | 0.030 |
Why?
|
| Plasmids | 1 | 2021 | 2307 | 0.030 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2018 | 434 | 0.030 |
Why?
|
| Veins | 1 | 2020 | 769 | 0.030 |
Why?
|
| Cell Line | 3 | 2020 | 15999 | 0.030 |
Why?
|
| Pentosyltransferases | 1 | 2015 | 65 | 0.030 |
Why?
|
| Homeodomain Proteins | 2 | 2021 | 2422 | 0.030 |
Why?
|
| Epitopes | 1 | 2022 | 2571 | 0.030 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2017 | 215 | 0.030 |
Why?
|
| Osteoblasts | 1 | 2021 | 1165 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2014 | 10949 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2006 | 3494 | 0.030 |
Why?
|
| Age Factors | 2 | 2009 | 18367 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2021 | 1382 | 0.030 |
Why?
|
| Alleles | 4 | 2015 | 6938 | 0.030 |
Why?
|
| Cystadenoma | 1 | 2015 | 84 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2020 | 1097 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2017 | 371 | 0.030 |
Why?
|
| Transfection | 2 | 2015 | 5892 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2017 | 462 | 0.030 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2015 | 82 | 0.030 |
Why?
|
| Technetium Tc 99m Aggregated Albumin | 1 | 2014 | 66 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1997 | 906 | 0.030 |
Why?
|
| Colon, Ascending | 1 | 2014 | 16 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2019 | 2335 | 0.030 |
Why?
|
| Purines | 1 | 2018 | 594 | 0.030 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2014 | 146 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 840 | 0.030 |
Why?
|
| Database Management Systems | 1 | 2016 | 270 | 0.030 |
Why?
|
| Breast | 1 | 2023 | 1969 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2016 | 548 | 0.030 |
Why?
|
| Fibroblast Growth Factor 3 | 1 | 2013 | 17 | 0.030 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2013 | 17 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 1999 | 1227 | 0.030 |
Why?
|
| RNA Interference | 2 | 2016 | 2890 | 0.030 |
Why?
|
| Nephritis | 1 | 2015 | 158 | 0.030 |
Why?
|
| Quality Control | 1 | 2017 | 843 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 1770 | 0.030 |
Why?
|
| Apoptosis | 3 | 2016 | 9728 | 0.030 |
Why?
|
| Kinetics | 1 | 2022 | 6474 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 13990 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2017 | 940 | 0.030 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2015 | 290 | 0.030 |
Why?
|
| Simplexvirus | 1 | 2017 | 802 | 0.030 |
Why?
|
| Pancreatic Ducts | 1 | 2015 | 328 | 0.030 |
Why?
|
| Liver Failure | 1 | 2015 | 241 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2008 | 3336 | 0.030 |
Why?
|
| Hyperphosphatemia | 1 | 2013 | 40 | 0.030 |
Why?
|
| Drug Delivery Systems | 2 | 2018 | 2218 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2014 | 299 | 0.030 |
Why?
|
| Microsatellite Repeats | 1 | 2016 | 802 | 0.030 |
Why?
|
| Hepatectomy | 1 | 2017 | 550 | 0.030 |
Why?
|
| bcl-X Protein | 1 | 2015 | 411 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 2014 | 321 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2014 | 708 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2018 | 4044 | 0.030 |
Why?
|
| Receptor, Notch1 | 1 | 2016 | 502 | 0.030 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2014 | 361 | 0.030 |
Why?
|
| ROC Curve | 1 | 2021 | 3527 | 0.030 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2014 | 188 | 0.030 |
Why?
|
| Idarubicin | 1 | 2012 | 62 | 0.030 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2012 | 43 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2019 | 1341 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 2 | 2012 | 4465 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2014 | 408 | 0.030 |
Why?
|
| Random Allocation | 1 | 2017 | 2427 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2015 | 608 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 503 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 972 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2022 | 2924 | 0.030 |
Why?
|
| Glycolysis | 1 | 2016 | 826 | 0.030 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2012 | 83 | 0.030 |
Why?
|
| World Health Organization | 1 | 2017 | 1318 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2012 | 25618 | 0.030 |
Why?
|
| Protein Binding | 3 | 2017 | 9392 | 0.030 |
Why?
|
| Japan | 1 | 2016 | 1361 | 0.020 |
Why?
|
| GTP-Binding Protein alpha Subunits | 1 | 2012 | 100 | 0.020 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2012 | 140 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2015 | 2645 | 0.020 |
Why?
|
| Vaccination | 1 | 2023 | 3278 | 0.020 |
Why?
|
| Cardia | 1 | 2011 | 57 | 0.020 |
Why?
|
| Valine | 1 | 2013 | 413 | 0.020 |
Why?
|
| Tissue Embedding | 1 | 2011 | 43 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2015 | 1907 | 0.020 |
Why?
|
| Case-Control Studies | 3 | 2020 | 21752 | 0.020 |
Why?
|
| Neuroglia | 1 | 2016 | 927 | 0.020 |
Why?
|
| DNA-Cytosine Methylases | 1 | 2010 | 17 | 0.020 |
Why?
|
| Membrane Transport Proteins | 1 | 2016 | 1028 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2019 | 1509 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 3474 | 0.020 |
Why?
|
| Azacitidine | 1 | 2012 | 347 | 0.020 |
Why?
|
| Mutagenesis | 2 | 2008 | 1267 | 0.020 |
Why?
|
| Veratrum Alkaloids | 1 | 2010 | 25 | 0.020 |
Why?
|
| Cytarabine | 1 | 2012 | 692 | 0.020 |
Why?
|
| Heterozygote | 2 | 2007 | 2805 | 0.020 |
Why?
|
| Prostatic Neoplasms | 2 | 2011 | 11074 | 0.020 |
Why?
|
| Liver | 1 | 2006 | 7472 | 0.020 |
Why?
|
| DNA Repair | 1 | 2000 | 2046 | 0.020 |
Why?
|
| Introns | 1 | 2013 | 991 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 664 | 0.020 |
Why?
|
| Culture | 1 | 2014 | 633 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 644 | 0.020 |
Why?
|
| Organophosphorus Compounds | 1 | 2011 | 215 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2018 | 35423 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2011 | 677 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 2279 | 0.020 |
Why?
|
| Western World | 1 | 2009 | 27 | 0.020 |
Why?
|
| Pulmonary Alveoli | 1 | 2013 | 675 | 0.020 |
Why?
|
| Immunotherapy | 2 | 2016 | 4440 | 0.020 |
Why?
|
| Adenosine Triphosphatases | 1 | 2014 | 839 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2011 | 500 | 0.020 |
Why?
|
| Patient Selection | 2 | 2012 | 4216 | 0.020 |
Why?
|
| Smad2 Protein | 1 | 2009 | 156 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2022 | 8321 | 0.020 |
Why?
|
| Neural Stem Cells | 1 | 2016 | 850 | 0.020 |
Why?
|
| Neurosecretory Systems | 1 | 2011 | 231 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2011 | 553 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2023 | 6196 | 0.020 |
Why?
|
| Pregnancy | 1 | 2011 | 29142 | 0.020 |
Why?
|
| Phylogeny | 1 | 2016 | 2803 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 1107 | 0.020 |
Why?
|
| Stem Cells | 1 | 2022 | 3567 | 0.020 |
Why?
|
| Colonic Polyps | 1 | 2014 | 542 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2013 | 1791 | 0.020 |
Why?
|
| Canada | 1 | 2014 | 2065 | 0.020 |
Why?
|
| Cell Dedifferentiation | 1 | 2009 | 135 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2017 | 1928 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 2 | 2008 | 2088 | 0.020 |
Why?
|
| Microfluidics | 1 | 2014 | 662 | 0.020 |
Why?
|
| Co-Repressor Proteins | 1 | 2009 | 194 | 0.020 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2011 | 338 | 0.020 |
Why?
|
| DNA | 1 | 2023 | 7303 | 0.020 |
Why?
|
| Microglia | 1 | 2017 | 1266 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2016 | 8950 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2014 | 2970 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2015 | 1782 | 0.020 |
Why?
|
| Chromatin | 1 | 2020 | 2934 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 2726 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2010 | 270 | 0.020 |
Why?
|
| Cell Separation | 1 | 2014 | 1751 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1997 | 2234 | 0.020 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2009 | 314 | 0.020 |
Why?
|
| Heterochromatin | 1 | 2011 | 296 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2019 | 2003 | 0.020 |
Why?
|
| Australia | 1 | 2011 | 1169 | 0.020 |
Why?
|
| Gadolinium | 1 | 2013 | 952 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 1903 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2015 | 1904 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 1504 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 2886 | 0.020 |
Why?
|
| Autophagy | 1 | 2015 | 1300 | 0.020 |
Why?
|
| Carcinoma, Large Cell | 1 | 2008 | 113 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 1836 | 0.020 |
Why?
|
| Intranuclear Inclusion Bodies | 1 | 2007 | 37 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2016 | 2967 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2013 | 1169 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2011 | 1584 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2022 | 4935 | 0.020 |
Why?
|
| Ribonucleases | 1 | 2007 | 287 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2011 | 1950 | 0.020 |
Why?
|
| C-Peptide | 1 | 2008 | 419 | 0.020 |
Why?
|
| Cell Nucleolus | 1 | 2007 | 166 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2014 | 1677 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 3509 | 0.020 |
Why?
|
| Hospitals | 1 | 2020 | 3952 | 0.020 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2009 | 625 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 2702 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2011 | 1677 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 2914 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 1799 | 0.020 |
Why?
|
| Antigens, CD | 1 | 1997 | 4026 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2017 | 2211 | 0.020 |
Why?
|
| Comorbidity | 1 | 2020 | 10387 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 1999 | 9735 | 0.020 |
Why?
|
| Fibrosis | 1 | 2013 | 2029 | 0.020 |
Why?
|
| CpG Islands | 1 | 2010 | 1172 | 0.020 |
Why?
|
| Fibroblasts | 2 | 2011 | 4156 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2011 | 1726 | 0.020 |
Why?
|
| Asia | 1 | 2007 | 610 | 0.020 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2008 | 323 | 0.020 |
Why?
|
| Lymphokines | 1 | 2009 | 949 | 0.020 |
Why?
|
| Pan troglodytes | 1 | 2006 | 229 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2013 | 1707 | 0.020 |
Why?
|
| Portal Vein | 1 | 2008 | 437 | 0.020 |
Why?
|
| Creatinine | 1 | 2011 | 1919 | 0.020 |
Why?
|
| Factor V | 1 | 2006 | 178 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2006 | 528 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2015 | 1940 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2010 | 1097 | 0.020 |
Why?
|
| Geography | 1 | 2007 | 670 | 0.020 |
Why?
|
| Hedgehog Proteins | 1 | 2010 | 783 | 0.020 |
Why?
|
| Endocytosis | 2 | 2000 | 985 | 0.020 |
Why?
|
| Cadherins | 1 | 2009 | 907 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2020 | 4599 | 0.020 |
Why?
|
| Gene Targeting | 1 | 2008 | 880 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2006 | 528 | 0.020 |
Why?
|
| Adipokines | 1 | 2006 | 319 | 0.020 |
Why?
|
| Energy Metabolism | 1 | 2015 | 2895 | 0.020 |
Why?
|
| Genetics, Population | 1 | 2009 | 934 | 0.020 |
Why?
|
| Lectins | 1 | 2006 | 513 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 2662 | 0.020 |
Why?
|
| Ascites | 1 | 2006 | 344 | 0.010 |
Why?
|
| Precancerous Conditions | 1 | 2011 | 975 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 3086 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 2942 | 0.010 |
Why?
|
| Genomic Instability | 1 | 2008 | 695 | 0.010 |
Why?
|
| Observer Variation | 1 | 2010 | 2593 | 0.010 |
Why?
|
| Acute Disease | 2 | 2012 | 7148 | 0.010 |
Why?
|
| Atrophy | 1 | 2008 | 1582 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2007 | 1590 | 0.010 |
Why?
|
| Ovarian Neoplasms | 2 | 2011 | 4837 | 0.010 |
Why?
|
| Recurrence | 1 | 2015 | 8343 | 0.010 |
Why?
|
| Vena Cava, Inferior | 1 | 2006 | 436 | 0.010 |
Why?
|
| Janus Kinase 2 | 1 | 2006 | 528 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 15538 | 0.010 |
Why?
|
| Aging | 1 | 2022 | 8661 | 0.010 |
Why?
|
| Motor Neurons | 1 | 2007 | 855 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 1372 | 0.010 |
Why?
|
| Macrophages | 1 | 2017 | 5657 | 0.010 |
Why?
|
| Models, Biological | 1 | 1999 | 9582 | 0.010 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2007 | 1094 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 25043 | 0.010 |
Why?
|
| Ligands | 1 | 2009 | 3294 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2008 | 2634 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2010 | 6367 | 0.010 |
Why?
|
| Species Specificity | 1 | 2006 | 2480 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 9960 | 0.010 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2008 | 828 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2009 | 1787 | 0.010 |
Why?
|
| Haloperidol | 1 | 1983 | 397 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2006 | 1586 | 0.010 |
Why?
|
| Haplotypes | 1 | 2007 | 2781 | 0.010 |
Why?
|
| Mass Screening | 1 | 2017 | 5252 | 0.010 |
Why?
|
| Apolipoproteins E | 1 | 2006 | 1438 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2006 | 1114 | 0.010 |
Why?
|
| Antibodies | 1 | 2009 | 2461 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2011 | 5974 | 0.010 |
Why?
|
| Neovascularization, Physiologic | 1 | 2007 | 1351 | 0.010 |
Why?
|
| Zebrafish Proteins | 1 | 2006 | 1004 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2010 | 2478 | 0.010 |
Why?
|
| Fetus | 1 | 2007 | 1880 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2011 | 3036 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 2 | 1999 | 3772 | 0.010 |
Why?
|
| Contrast Media | 1 | 2013 | 5300 | 0.010 |
Why?
|
| London | 1 | 2000 | 233 | 0.010 |
Why?
|
| p21-Activated Kinases | 1 | 2000 | 128 | 0.010 |
Why?
|
| Spinal Cord | 1 | 2007 | 1809 | 0.010 |
Why?
|
| Homosexuality | 1 | 2000 | 264 | 0.010 |
Why?
|
| HLA-B7 Antigen | 1 | 1998 | 48 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2000 | 898 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2006 | 2263 | 0.010 |
Why?
|
| Gene Duplication | 1 | 2000 | 330 | 0.010 |
Why?
|
| Clathrin | 1 | 1999 | 267 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2000 | 936 | 0.010 |
Why?
|
| Macaca | 1 | 1999 | 440 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2006 | 1939 | 0.010 |
Why?
|
| Logistic Models | 1 | 2012 | 13409 | 0.010 |
Why?
|
| Spinal Cord Diseases | 1 | 1980 | 299 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2010 | 3328 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 7723 | 0.010 |
Why?
|
| Golgi Apparatus | 1 | 1998 | 410 | 0.010 |
Why?
|
| Prevalence | 1 | 2013 | 15226 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 1999 | 853 | 0.010 |
Why?
|
| Surface Properties | 1 | 1999 | 1184 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2008 | 2875 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1999 | 1724 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 3508 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2000 | 2839 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 12075 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2007 | 3478 | 0.010 |
Why?
|
| src-Family Kinases | 1 | 1997 | 551 | 0.010 |
Why?
|
| Sarcoidosis | 1 | 1980 | 505 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1999 | 2557 | 0.010 |
Why?
|
| Insulin | 1 | 2008 | 6583 | 0.010 |
Why?
|
| HIV Infections | 1 | 2000 | 16718 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 2000 | 19227 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2006 | 5982 | 0.010 |
Why?
|
| Infant | 1 | 2012 | 35129 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2011 | 23337 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1980 | 1885 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2007 | 21824 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1998 | 3748 | 0.000 |
Why?
|
| Schizophrenia | 1 | 1983 | 6882 | 0.000 |
Why?
|
| United States | 1 | 2011 | 69867 | 0.000 |
Why?
|
| Prolactin | 1 | 1983 | 669 | 0.000 |
Why?
|
| Myelography | 1 | 1980 | 69 | 0.000 |
Why?
|
| Schizophrenic Psychology | 1 | 1983 | 1678 | 0.000 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1983 | 6037 | 0.000 |
Why?
|